Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis, according to a new study, published in the May 30 online edition of Arthritis Care & Research.
Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis (JIA), according to a new study, published in the May 30 online edition of Arthritis Care & Research.
In the retrospective study, led by Araine Klein with Asklepios Klinik Sankt Augustin, in Germany, researchers reviewed 411 patients with JIA who received methotrexate (MTX) for at least 6 months. Patients in both the oral therapy and subcutaneous groups showed a high clinical response (73% for oral vs 72% for injection). In addition, 22% of patients who received oral MTX had at least 1 adverse event, compared to 27% in the subcutaneous group.
However, significantly more patients with subcutaneous application discontinued MTX because of adverse events (11%) compared to oral (5%).
“In this retrospective analysis, parenteral MTX was not superior to oral administration, regarding efficacy and tolerability,” the researchers wrote.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More